相关临床试验
554
49 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1877
进行中（未招募）
22
4.0%
已完成
287
51.8%
Enrolling By Invitation
4
0.7%
尚未招募
23
4.2%
招募中
65
11.7%
暂停
5
0.9%
终止
44
7.9%
Unknown
85
15.3%
撤回
19
3.4%
暂无批准数据
- Restart Life Sciences reported 146% sequential revenue growth for the second quarter of 2026, driven by its Holy Crap functional food brand. - The Company secured a Walmart Canada online marketplace listing and entered the U.S. market through Amazon USA, alongside a Caribbean market pilot. - Restart Life Sciences is developing specialized protein-focused formulations targeting youth and senior consumer segments following collaboration with the University of Manitoba's Richardson Centre. - Management continues to evaluate merger and acquisition opportunities within the health and CPG sectors to support future revenue growth.
- The TRACTION trial demonstrated that tranexamic acid reduced the need for red blood cell transfusions by 31% in patients undergoing high-risk non-cardiac surgeries compared to placebo. - Among 8,273 patients across 10 Canadian hospitals, tranexamic acid lowered transfusion rates from 9.8% to 7.4% without increasing venous thromboembolism risk. - The findings suggest broad implementation could prevent 5-10 million units of perioperative red cell transfusions annually in the estimated 100 million non-cardiac surgeries performed yearly. - The inexpensive, widely available drug showed particular safety in cancer patients, who comprised 60.5% of the study population and face elevated thrombosis risk.
- Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment. - The non-light activated therapy showed promising safety and efficacy in animal models, potentially offering new hope for billions affected by HSV infections worldwide. - Researchers plan to advance the development of both a therapeutic treatment and preventive vaccine for HSV, with clinical trials to follow these successful preclinical results.
- Advanced risk stratification models are enabling precise identification of high-risk CKD patients and connecting them with appropriate therapies, bridging the gap between diagnostics and treatment. - Population health strategies, particularly leveraging laboratory data as a safety net, are crucial for addressing CKD care disparities in marginalized communities and ensuring continuous patient monitoring. - Moving beyond the traditional EGFR-centered approach, new risk-prediction models can identify high-risk patients across all CKD stages, enabling early intervention with targeted therapies.
